Cancer biomarker Market Research Report- Global Forecast till 2032

Cancer Biomarker Market Research Report Information By Type (Protein Biomarker and Genetic Biomarker), By Application (Diagnostic, Prognostic, and Therapeutic), By End-User (Pharmaceutical & Biotechnology Companies, and Diagnostic Companies), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2032

ID: MRFR/Pharma/3935-CR | 85 Pages | Author: Rahul Gotadki | January 2018         

1 Report Prologue

2 Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3 Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

4 Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5 Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

6 Global Cancer Biomarker Market, By Types

6.1 Introduction

6.2 Protein Biomarker

6.3 Genetic Biomarker

6.4 Others

7 Global Cancer Biomarker Market, By Application

7.1 Introduction

7.2 Diagnostic

7.2.1 Imaging

7.2.2 Non- Imaging

7.3 Prognostic

7.4 Therapeutic

8 Global Cancer Biomarker Market, By End Users

8.1 Introduction

8.2 Pharma & Biotech Companies

8.3 Diagnostic Tool Companies

8.4 Healthcare IT/Big Data Companies

8.5 Clinical Laboratories

9 Global Cancer Biomarker Market, by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 US

9.2.1.1 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 U.K

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

11 Company Profiles

11.1 F. Hoffmann-La Roche AG

11.1.1 Company Overview

11.1.2 Financials

11.1.3 Products

11.1.4 Strategy

11.1.5 Key Developments

11.2 Becton Dickinson

11.2.1 Company Overview

11.2.2 Financials

11.2.3 Products

11.2.4 Strategy

11.2.5 Key Developments

11.3 Abbott Laboratories

11.3.1 Company Overview

11.3.2 Financials

11.3.3 Products

11.3.4 Strategy

11.3.5 Key Developments

11.4 PerkinElmer, Inc.

11.4.1 Company Overview

11.4.2 Financials

11.4.3 Products

11.4.4 Strategy

11.4.5 Key Developments

11.5 Bristol-Myers Squibb

11.5.1 Company Overview

11.5.2 Financials

11.5.3 Products

11.5.4 Strategy

11.5.5 Key Developments

11.6 Bio-Rad Laboratories

11.6.1 Company Overview

11.6.2 Financials

11.6.3 Products

11.6.4 Strategy

11.6.5 Key Developments

11.7 Eli Lilly and Company

11.7.1 Company Overview

11.7.2 Financials

11.7.3 Products

11.7.4 Strategy

11.7.5 Key Developments

11.8 Merck & Co., Inc

11.8.1 Company Overview

11.8.2 Financials

11.8.3 Products

11.8.4 Strategy

11.8.5 Key Developments

11.9 Pfizer Inc.

11.9.1 Company Overview

11.9.2 Financials

11.9.3 Products

11.9.4 Strategy

11.9.5 Key Developments

11.10 GlaxoSmithKline plc.

11.10.1 Company Overview

11.10.2 Financials

11.10.3 Products

11.10.4 Strategy

11.10.5 Key Developments

11.11 QIAGEN N.V

11.11.1 Company Overview

11.11.2 Financials

11.11.3 Products

11.11.4 Strategy

11.11.5 Key Developments

 11.12 Novartis AG

11.12.1 Company Overview

11.12.2 Financials

11.12.3 Products

11.12.4 Strategy

11.12.5 Key Developments

11.13 Thermo Fisher Scientific Inc.

11.13.1 Company Overview

11.13.2 Financials

11.13.3 Products

11.13.4 Strategy

11.13.5 Key Developments

11.14 Illumina Inc.

11.14.1 Company Overview

11.14.2 Financials

11.14.3 Products

11.14.4 Strategy

11.14.5 Key Developments

11.15 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Medical End Users Industry

Chapter 13 Appendix

12 List of Tables

Table 1 Cancer Biomarker Industry Synopsis, 2020 – 2027

Table 2 Global Cancer Biomarker Market Estimates and Forecast, 2020 – 2027, (USD Million)

Table 3 Global Cancer Biomarker Market by Region, 2020 – 2027, (USD Million)

Table 4 Global Cancer Biomarker Market by Type, 2020 – 2027, (USD Million)

Table 5 Global Cancer Biomarker Market by Application, 2020 – 2027, (USD Million)

Table 6 Global Cancer Biomarker Market by End Users, 2020 – 2027, (USD Million)

Table 7 North America Cancer Biomarker Market by Type, 2020 – 2027, (USD Million)

Table 8 North America Cancer Biomarker Market by Application, 2020 – 2027, (USD Million)

Table 9 North America Cancer Biomarker Market by End Users, 2020 – 2027, (USD Million)

Table 10 US Cancer Biomarker Market by Type, 2020 – 2027, (USD Million)

Table 11 US Cancer Biomarker Market by Application, 2020 – 2027, (USD Million)

Table 12 US Cancer Biomarker Market by End Users, 2020 – 2027, (USD Million)

Table 13 Canada Market by Type, 2020 – 2027, (USD Million)

Table 14 Canada Cancer Biomarker Market by Application, 2020 – 2027, (USD Million)

Table 15 Canada Cancer Biomarker Market by End Users, 2020 – 2027, (USD Million)

Table 16 South America Cancer Biomarker Market by Type, 2020 – 2027, (USD Million)

Table 17 South America Cancer Biomarker Market by Application, 2020 – 2027, (USD Million)

Table 18 South America Cancer Biomarker Market by End Users, 2020 – 2027, (USD Million)

Table 19 Europe Cancer Biomarker Market by Type, 2020 – 2027, (USD Million)

Table 20 Europe Cancer Biomarker Market by Application, 2020 – 2027, (USD Million)

Table 21 Europe Cancer Biomarker Market by End Users, 2020 – 2027, (USD Million)

Table 22 Western Europe Cancer Biomarker Market by Type, 2020 – 2027, (USD Million)

Table 23 Western Europe Cancer Biomarker Market by Application, 2020 – 2027, (USD Million)

Table 24 Western Europe Cancer Biomarker Market by End Users, 2020 – 2027, (USD Million)

Table 25 Eastern Europe Cancer Biomarker Market by Type, 2020 – 2027, (USD Million)

Table 26 Eastern Europe Cancer Biomarker Market by Application, 2020 – 2027, (USD Million)

Table 27 Eastern Europe Cancer Biomarker Market by End Users, 2020 – 2027, (USD Million)

Table 28 Asia Pacific Cancer Biomarker Market by Type, 2020 – 2027, (USD Million)

Table 29 Asia Pacific Cancer Biomarker Market by Application, 2020 – 2027, (USD Million)

Table 30 Asia Pacific Cancer Biomarker Market by End Users, 2020 – 2027, (USD Million)

Table 31 Middle East & Africa Cancer Biomarker Market by Type, 2020 – 2027, (USD Million)

Table 32 Middle East & Africa Cancer Biomarker Market by Application, 2020 – 2027, (USD Million)

Table 33 Middle East & Africa Cancer Biomarker Market by End Users, 2020 – 2027, (USD Million)

13 List of Figures

Figure 1 Research Process

Figure 2 Segmentation for Global Cancer Biomarker Market

Figure 3 Segmentation Market Dynamics for Global Cancer Biomarker Market

Figure 4 Global Cancer Biomarker market Share, by Type 2020

Figure 5 Global Cancer Biomarker market Share, by Application 2020

Figure 6 Global Cancer Biomarker Market Share, by End Users, 2020

Figure 7 Global Cancer Biomarker Market Share, by Region, 2020

Figure 8 North America Cancer Biomarker Market Share, by Country, 2020

Figure 9 Europe Cancer Biomarker Market Share, by Country, 2020

Market Segmentation Tab


Global Cancer Biomarker, By Type Outlook (USD Billion, 2019-2030)




  • Protein Biomarker




  • Genetic Biomarker




Global Cancer Biomarker, By Application Outlook (USD Billion, 2019-2030)




  • Diagnostic




  • Prognostic




  • Therapeutic




Global Cancer Biomarker, By End User Outlook (USD Billion, 2019-2030)




  • Pharmaceutical & Biotechnology Companies




  • Diagnostic Companies




Global Cancer Biomarker Regional Outlook (USD Billion, 2019-2030)




  • North America Outlook (USD Billion, 2019-2030)




  • North America Cancer Biomarker, By Type Outlook (USD Billion, 2019-2030)




    • Protein Biomarker




    • Genetic Biomarker






  • North America Cancer Biomarker, By Application Outlook (USD Billion, 2019-2030)




    • Diagnostic




    • Prognostic




    • Therapeutic






  • North America Cancer Biomarker, By End User Outlook (USD Billion, 2019-2030)




    • Pharmaceutical & Biotechnology Companies




    • Diagnostic Companies




    • US Outlook (USD Billion, 2019-2030)




    • US Cancer Biomarker, By Type Outlook (USD Billion, 2019-2030)




      • Protein Biomarker




      • Genetic Biomarker






    • US Cancer Biomarker, By Application Outlook (USD Billion, 2019-2030)




      • Diagnostic




      • Prognostic




      • Therapeutic






    • US Cancer Biomarker, By End User Outlook (USD Billion, 2019-2030)




      • Pharmaceutical & Biotechnology Companies




      • Diagnostic Companies






    • Canada Outlook (USD Billion, 2019-2030)




    • Canada Cancer Biomarker, By Type Outlook (USD Billion, 2019-2030)




      • Protein Biomarker




      • Genetic Biomarker






    • Canada Cancer Biomarker, By Application Outlook (USD Billion, 2019-2030)




      • Diagnostic




      • Prognostic




      • Therapeutic






    • Canada Cancer Biomarker, By End User Outlook (USD Billion, 2019-2030)




      • Pharmaceutical & Biotechnology Companies




      • Diagnostic Companies








  • Europe Outlook (USD Billion, 2019-2030)




  • Europe Cancer Biomarker, By Type Outlook (USD Billion, 2019-2030)




    • Protein Biomarker




    • Genetic Biomarker






  • Europe Cancer Biomarker, By Application Outlook (USD Billion, 2019-2030)




    • Diagnostic




    • Prognostic




    • Therapeutic






  • Europe Cancer Biomarker, By End User Outlook (USD Billion, 2019-2030)




    • Pharmaceutical & Biotechnology Companies




    • Diagnostic Companies




    • Germany Outlook (USD Billion, 2019-2030)




    • Germany Cancer Biomarker, By Type Outlook (USD Billion, 2019-2030)




      • Protein Biomarker




      • Genetic Biomarker






    • Germany Cancer Biomarker, By Application Outlook (USD Billion, 2019-2030)




      • Diagnostic




      • Prognostic




      • Therapeutic






    • Germany Cancer Biomarker, By End User Outlook (USD Billion, 2019-2030)




      • Pharmaceutical & Biotechnology Companies




      • Diagnostic Companies






    • France Outlook (USD Billion, 2019-2030)




    • France Cancer Biomarker, By Type Outlook (USD Billion, 2019-2030)




      • Protein Biomarker




      • Genetic Biomarker






    • France Cancer Biomarker, By Application Outlook (USD Billion, 2019-2030)




      • Diagnostic




      • Prognostic




      • Therapeutic






    • France Cancer Biomarker, By End User Outlook (USD Billion, 2019-2030)




      • Pharmaceutical & Biotechnology Companies




      • Diagnostic Companies






    • UK Outlook (USD Billion, 2019-2030)




    • UK Cancer Biomarker, By Type Outlook (USD Billion, 2019-2030)




      • Protein Biomarker




      • Genetic Biomarker






    • UK Cancer Biomarker, By Application Outlook (USD Billion, 2019-2030)




      • Diagnostic




      • Prognostic




      • Therapeutic






    • UK Cancer Biomarker, By End User Outlook (USD Billion, 2019-2030)




      • Pharmaceutical & Biotechnology Companies




      • Diagnostic Companies






    • Italy Outlook (USD Billion, 2019-2030)




    • Italy Cancer Biomarker, By Type Outlook (USD Billion, 2019-2030)




      • Protein Biomarker




      • Genetic Biomarker






    • Italy Cancer Biomarker, By Application Outlook (USD Billion, 2019-2030)




      • Diagnostic




      • Prognostic




      • Therapeutic






    • Italy Cancer Biomarker, By End User Outlook (USD Billion, 2019-2030)




      • Pharmaceutical & Biotechnology Companies




      • Diagnostic Companies






    • Rest of Europe Outlook (USD Billion, 2019-2030)




    • Rest of Europe Cancer Biomarker, By Type Outlook (USD Billion, 2019-2030)




      • Protein Biomarker




      • Genetic Biomarker






    • Rest of Europe Cancer Biomarker, By Application Outlook (USD Billion, 2019-2030)




      • Diagnostic




      • Prognostic




      • Therapeutic






    • Rest of Europe Cancer Biomarker, By End User Outlook (USD Billion, 2019-2030)




      • Pharmaceutical & Biotechnology Companies




      • Diagnostic Companies








  • Asia-Pacific Outlook (USD Billion, 2019-2030)




  • Asia-Pacific Cancer Biomarker, By Type Outlook (USD Billion, 2019-2030)




    • Protein Biomarker




    • Genetic Biomarker






  • Asia-Pacific Cancer Biomarker, By Application Outlook (USD Billion, 2019-2030)




    • Diagnostic




    • Prognostic




    • Therapeutic






  • Asia-Pacific Cancer Biomarker, By End User Outlook (USD Billion, 2019-2030)




    • Pharmaceutical & Biotechnology Companies




    • Diagnostic Companies




    • China Outlook (USD Billion, 2019-2030)




    • China Cancer Biomarker, By Type Outlook (USD Billion, 2019-2030)




      • Protein Biomarker




      • Genetic Biomarker














    • China Cancer Biomarker, By Application Outlook (USD Billion, 2019-2030)




      • Diagnostic




      • Prognostic




      • Therapeutic






    • China Cancer Biomarker, By End User Outlook (USD Billion, 2019-2030)




      • Pharmaceutical & Biotechnology Companies




      • Diagnostic Companies






    • India Outlook (USD Billion, 2019-2030)




    • India Cancer Biomarker, By Type Outlook (USD Billion, 2019-2030)




      • Protein Biomarker




      • Genetic Biomarker






    • India Cancer Biomarker, By Application Outlook (USD Billion, 2019-2030)




      • Diagnostic




      • Prognostic




      • Therapeutic






    • India Cancer Biomarker, By End User Outlook (USD Billion, 2019-2030)




      • Pharmaceutical & Biotechnology Companies




      • Diagnostic Companies






    • Japan Outlook (USD Billion, 2019-2030)




    • Japan Cancer Biomarker, By Type Outlook (USD Billion, 2019-2030)




      • Protein Biomarker




      • Genetic Biomarker






    • Japan Cancer Biomarker, By Application Outlook (USD Billion, 2019-2030)




      • Diagnostic




      • Prognostic




      • Therapeutic






    • Japan Cancer Biomarker, By End User Outlook (USD Billion, 2019-2030)




      • Pharmaceutical & Biotechnology Companies




      • Diagnostic Companies






    • South Korea Outlook (USD Billion, 2019-2030)




    • South Korea Cancer Biomarker, By Type Outlook (USD Billion, 2019-2030)




      • Protein Biomarker




      • Genetic Biomarker






    • South Korea Cancer Biomarker, By Application Outlook (USD Billion, 2019-2030)




      • Diagnostic




      • Prognostic




      • Therapeutic






    • South Korea Cancer Biomarker, By End User Outlook (USD Billion, 2019-2030)




      • Pharmaceutical & Biotechnology Companies




      • Diagnostic Companies






    • Australia Outlook (USD Billion, 2019-2030)




    • Australia Cancer Biomarker, By Type Outlook (USD Billion, 2019-2030)




      • Protein Biomarker




      • Genetic Biomarker






    • Australia Cancer Biomarker, By Application Outlook (USD Billion, 2019-2030)




      • Diagnostic




      • Prognostic




      • Therapeutic






    • Australia Cancer Biomarker, By End User Outlook (USD Billion, 2019-2030)




      • Pharmaceutical & Biotechnology Companies




      • Diagnostic Companies






    • Rest of Asia-Pacific Outlook (USD Billion, 2019-2030)




    • Rest of Asia-Pacific Cancer Biomarker, By Type Outlook (USD Billion, 2019-2030)




      • Protein Biomarker




      • Genetic Biomarker






    • Rest of Asia-Pacific Cancer Biomarker, By Application Outlook (USD Billion, 2019-2030)




      • Diagnostic




      • Prognostic




      • Therapeutic






    • Rest of Asia-Pacific Cancer Biomarker, By End User Outlook (USD Billion, 2019-2030)




      • Pharmaceutical & Biotechnology Companies




      • Diagnostic Companies







  • Rest of the World Outlook (USD Billion, 2019-2030)




  • Rest of the World Cancer Biomarker, By Type Outlook (USD Billion, 2019-2030)




    • Protein Biomarker




    • Genetic Biomarker






  • Rest of the World Cancer Biomarker, By Application Outlook (USD Billion, 2019-2030)




    • Diagnostic




    • Prognostic




    • Therapeutic






  • Rest of the World Cancer Biomarker, By End User Outlook (USD Billion, 2019-2030)




    • Pharmaceutical & Biotechnology Companies




    • Diagnostic Companies




    • Middle East & Africa Outlook (USD Billion, 2019-2030)




    • Middle East & Africa Cancer Biomarker, By Type Outlook (USD Billion, 2019-2030)




      • Protein Biomarker




      • Genetic Biomarker






    • Middle East & Africa Cancer Biomarker, By Application Outlook (USD Billion, 2019-2030)




      • Diagnostic




      • Prognostic




      • Therapeutic






    • Middle East & Africa Cancer Biomarker, By End User Outlook (USD Billion, 2019-2030)




      • Pharmaceutical & Biotechnology Companies




      • Diagnostic Companies






    • Latin America Outlook (USD Billion, 2019-2030)




    • Latin America Cancer Biomarker, By Type Outlook (USD Billion, 2019-2030)




      • Protein Biomarker




      • Genetic Biomarker






    • Latin America Cancer Biomarker, By Application Outlook (USD Billion, 2019-2030)




      • Diagnostic




      • Prognostic




      • Therapeutic






    • Latin America Cancer Biomarker, By End User Outlook (USD Billion, 2019-2030)




      • Pharmaceutical & Biotechnology Companies




      • Diagnostic Companies







Leading companies partner with us for data-driven Insights.
Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid